We are looking for high-value, truly differentiating first or best-in-class treatments in:
- Heart Failure, hypertension and atrial fibrillation
- Atherosclerosis and multiple CV risk factor management
- Metabolic (including obesity)
- Autosomal dominant polycystic kidney disease (ADPKD)
- Glomerular diseases (Alport, FSGS)
- IgA nephropathy (IgAN)
- Rheumatology
- Dermatology
- Disease modifying osteoarthiritis
- Nucleic acid sensing & inflammasome
- Tolerance induction
- Allergy
- MS and immuno-neurological diseases
- Neurodegenerative diseases
- Neuromuscular diseases
- Breast cancers
- Prostate cancers
- Lung cancers
- Colorectal and pancreatic cancers
- Radioligand therapy (RLT): novel isotopes, chelators vectors and targets
- Non-Hodgkin lymphoma (NHL)
- Acute myeloid leukemia (AML)/ Myelodysplastic syndrome (MDS)
- Multiple myeloma (MM)
- Non-malignant hematology